Caspian's KO-7246 Shows Durable Beta-Cell Regeneration in Diabetes Models
KURA sits 45% above its 52-week low of $7.358.
Summary
Caspian Therapeutics, Kura's separately financed subsidiary, presented comprehensive preclinical data for KO-7246 at EASD. The menin inhibitor regenerated functional beta-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models, with effects persisting after treatment cessation. In human islets, KO-7246 selectively increased beta-cell proliferation and improved glucose-responsive insulin secretion. Comparative data showed KO-7246's bona fide menin inhibition, while BMF-219 lacked menin activity and instead inhibited kinases like CDK9. This follows the September 9 launch of Caspian with $50 million in Series A funding. The data support KO-7246's potential as a best-in-class menin inhibitor for diabetes, with IND-enabling studies underway. A virtual investor event is scheduled for October 13, 2026.
At the time of this announcement, KURA was trading at $10.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.9M. The 52-week trading range was $7.36 to $13.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.